Published in Proc Natl Acad Sci U S A on June 01, 2015
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | NCT01307267
The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses. Immunity (2016) 0.81
Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination. Front Immunol (2016) 0.78
Immune based therapy for melanoma. Indian J Med Res (2016) 0.78
Intravital imaging reveals new ancillary mechanisms co-opted by cancer cells to drive tumor progression. F1000Res (2016) 0.75
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science (2003) 7.75
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol (2012) 4.44
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997) 3.89
4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med (1997) 3.31
In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med (2007) 2.89
Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice. J Clin Invest (2008) 2.52
Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol (1993) 2.40
NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol (1998) 2.11
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood (2010) 2.06
The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov (2012) 1.95
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest (2012) 1.92
During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion. J Immunol (2005) 1.81
Cutting edge: Expression of functional CD137 receptor by dendritic cells. J Immunol (2002) 1.70
Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J Immunol (1997) 1.62
Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother (2011) 1.46
Identification of regulatory functions for 4-1BB and 4-1BBL in myelopoiesis and the development of dendritic cells. Nat Immunol (2008) 1.42
Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci (2008) 1.42
CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation. J Immunol (2011) 1.36
Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res (2002) 1.36
Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res (2013) 1.33
Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J Exp Med (2013) 1.29
Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest (2014) 1.29
Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res (2011) 1.23
Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J Immunol (2000) 1.18
CD137 promotes proliferation and survival of human B cells. J Immunol (2009) 1.12
Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One (2013) 1.12
Differential localization of T-bet and Eomes in CD8 T cell memory populations. J Immunol (2013) 1.09
Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res (2013) 1.05
Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice. PLoS One (2010) 1.02
The contextual role of TNFR family members in CD8(+) T-cell control of viral infections. Immunol Rev (2013) 0.97
Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. Mol Ther (2012) 0.96
T-Bet and Eomes Regulate the Balance between the Effector/Central Memory T Cells versus Memory Stem Like T Cells. PLoS One (2013) 0.90
Manipulating immune cells for adoptive immunotherapy of cancer. Curr Opin Immunol (2014) 0.89
Contribution of 4-1BBL on radioresistant cells in providing survival signals through 4-1BB expressed on CD8⁺ memory T cells in the bone marrow. Eur J Immunol (2012) 0.83
Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb. J Immunother Cancer (2013) 0.81